Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

The sought-after state of herd immunity — in which widespread outbreaks are prevented because enough people in a community are immune to a disease — is complicated by open questions about the effectiveness of a future vaccine and how COVID-19 spreads.

Why it matters: Unless a sufficient level of immunity is achieved in the population, the coronavirus could circulate indefinitely and potentially flare up as future outbreaks.

"When it comes to an infectious disease, herd immunity is essential to stopping its spread and ceasing to be a major health problem."
— Amesh Adalja, senior scholar, Johns Hopkins Center for Health Security

Where it stands: The magic number often cited is a minimum of 60% of the population would need to have immunity.

  • Right now, antibody studies indicate the world isn't close to that threshold, the NYT reports.
  • In hard-hit New York, for example, a recent study found 19.9% of people tested have antibodies to SARS-CoV-2. (Though even that is debated by researchers.)
  • And in Sweden, which took (controversial) relaxed measures in controlling the coronavirus, just 7.3% of Stockholm's population developed antibodies by April.

The catch: Antibodies are only meaningful to herd immunity if they provide lasting protection from a virus after someone is infected or vaccinated. But with the novel coronavirus, it's unknown how much immunity a person has after being infected — and for how long.

  • While not about SARS-CoV-2, a recent study, yet to be peer-reviewed, measured the level of antibodies to four other seasonal human coronaviruses in 10 people over a period of 35 years and found the antibody levels dropped as soon as six months after infection.
  • They also found people were frequently reinfected with the same virus after 12 months.
  • "An alarmingly short duration of protective immunity to coronaviruses was found," the authors from Amsterdam UMC wrote.

"There is not a consensus for what herd immunity looks like for this disease," says Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine.

  • Sarah Cobey, associate professor at the University of Chicago, agrees and tells Axios herd immunity may require more than 60%.
  • But some researchers have suggested that because different populations seem to be more susceptible to the disease, herd immunity may be achieved at lower levels.

"The biggest obstacle right now is that we have no vaccine. ... Then it will be distribution to the world's population. And, after that, you'd really be looking at [whether] the uptake is high enough or are there pockets of people who don't want to get the vaccine," Adalja says.

  • In order for a vaccine to bring herd immunity, both its efficacy and the percentage of people immunized would have to be high, Hotez says.
  • He and his colleagues estimate a COVID-19 vaccine would have to have an efficacy of 70% to prevent or extinguish an epidemic without social distancing and other measures, according to a recent preprint study.

But vaccinating large swathes of the population may be challenging.

  • Recent polls find between about 50% and 70% of Americans say they would get a COVID-19 vaccine if it became available.
  • Still, Adalja points out that as opposed to a highly contagious disease like the measles — which requires over 90% herd immunity — small pockets of anti-vax resistance likely won't stymie efforts to contain COVID-19.

Yes, but: Concern about anti-vaxxers is growing. Joe Smyser, CEO of the Public Good Projects, tracks the anti-vaccination movement and recently launched a digital tool called Project VCTR.

  • In a press conference last week, he said anti-vax messages on social media have tripled since the pandemic started.

What to watch: Over time, the virus could settle into a regular seasonal pattern not so different from coronaviruses that cause the common cold, recent research by Harvard epidemiologist Marc Lipsitch suggests.

  • In the near term, that could set up the virus for future outbreaks, like those seen with measles, or, if it evolves, the emergence of another strain of the virus that humans have never encountered.
  • Even with herd immunity, "there are going to be pockets of people who have lower [immunity] coverage, and you still have the opportunity for there to be small outbreaks. So it doesn't hurt to be vaccinating well above the minimum," Cobey says.
  • Eventually, it's possible that as at least part of the population becomes immune, the effects of the virus could become milder, the Washington Post reports.

Go deeper

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Health: CDC director defends agency's response to pandemic — CDC warns highly transmissible coronavirus variant could become dominant in U.S. in March.
  2. Politics: Biden readies massive shifts in policy for his first days in office.
  3. Vaccine: Fauci: 100 million doses in 100 days is "absolutely" doable.
  4. Economy: Unemployment filings explode again.
  5. Tech: Kids' screen time sees a big increase.
  6. World: WHO team arrives in China to investigate pandemic origins.
Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Health: CDC director defends agency's response to pandemic — CDC warns highly transmissible coronavirus variant could become dominant in U.S. in March.
  2. Politics: Biden readies massive shifts in policy for his first days in office.
  3. Vaccine: Fauci: 100 million doses in 100 days is "absolutely" doable.
  4. Economy: Unemployment filings explode again.
  5. Tech: Kids' screen time sees a big increase.
  6. World: WHO team arrives in China to investigate pandemic origins.
Dave Lawler, author of World
6 hours ago - World

Alexey Navalny detained after landing back in Moscow

Navalny and his wife shortly before he was detained. Photo: Kirill Kudryavtsev/AFP via Getty

Russian opposition leader Alexey Navalny was detained upon his return to Moscow on Sunday, which came five months after he was poisoned with the nerve agent Novichok. He returned despite being warned that he would be arrested.

The latest: Navalny was stopped at a customs checkpoint and led away alone by officers. He appeared to hug his wife goodbye, and his spokesman reports that his lawyer was not allowed to accompany him.